JSPR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
JSPR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Jasper Therapeutics's share price for the quarter that ended in Mar. 2024 was $29.36. Jasper Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 15.09 Mil. Therefore, Jasper Therapeutics's market cap for the quarter that ended in Mar. 2024 was $442.91 Mil.
Jasper Therapeutics's quarterly market cap increased from Sep. 2023 ($77.60 Mil) to Dec. 2023 ($88.08 Mil) and increased from Dec. 2023 ($88.08 Mil) to Mar. 2024 ($442.91 Mil).
Jasper Therapeutics's annual market cap declined from Dec. 2021 ($297.16 Mil) to Dec. 2022 ($18.37 Mil) but then increased from Dec. 2022 ($18.37 Mil) to Dec. 2023 ($88.08 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Jasper Therapeutics's Enterprise Value for Today is $253.98 Mil.
The historical data trend for Jasper Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jasper Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Market Cap | - | 297.16 | 18.37 | 88.08 |
Jasper Therapeutics Quarterly Data | |||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Market Cap | Get a 7-Day Free Trial | 198.06 | 151.80 | 77.60 | 88.08 | 442.91 |
For the Biotechnology subindustry, Jasper Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Jasper Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Jasper Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
Market Cap (A: Dec. 2023 ) | = | Share Price (A: Dec. 2023 ) | * | Shares Outstanding (EOP) (A: Dec. 2023 ) |
= | $7.89 | * | 11.1639 | |
= | $88.08 |
Jasper Therapeutics's Market Cap for the quarter that ended in Mar. 2024 is calculated as
Market Cap (Q: Mar. 2024 ) | = | Share Price (Q: Mar. 2024 ) | * | Shares Outstanding (EOP) (Q: Mar. 2024 ) |
= | $29.36 | * | 15.0856 | |
= | $442.91 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jasper Therapeutics (NAS:JSPR) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Jasper Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas G Wiggans | director | |
William Lis | director | PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Jeetinder Singh Mahal | officer: Chief Operating Officer | C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065 |
Ron Martell | director, officer: President, CEO & Director | PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111 |
Herb Cross | officer: Chief Financial Officer | 3061 ZANKER RD, SAN JOSE CA 95134 |
Scott C. Brun | director | C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104 |
Edwin Jonathan Tucker | officer: Chief Medical Officer | C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404 |
Anna Louise French | director | C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004 |
Kurt Von Emster | director, 10 percent owner | 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080 |
Gary E Rieschel | 10 percent owner | |
Qiming U.s. Healthcare Fund Ii, L.p. | 10 percent owner | 350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004 |
Llp Abingworth | 10 percent owner | 38 JERMYN STREET, LONDON X0 SW1Y 6DN |
Mark Mcdade | 10 percent owner | C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040 |
Qiming U.s. Healthcare Gp Ii, Llc | 10 percent owner | 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004 |
Carlyle Group Inc. | 10 percent owner | C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004 |
From GuruFocus
By Stock market mentor Stock market mentor • 01-04-2023
By sperokesalga sperokesalga • 02-17-2023
By Marketwired • 06-22-2023
By sperokesalga sperokesalga • 03-23-2023
By Marketwired • 09-25-2023
By sperokesalga sperokesalga • 06-20-2023
By sperokesalga sperokesalga • 06-13-2023
By Marketwired • 08-02-2023
By sperokesalga sperokesalga • 03-31-2023
By Stock market mentor Stock market mentor • 01-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.